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Purpose: To describe the clinical and molecular characteristics of patients with childhood-onset Stargardt
disease (STGD).
Design: Retrospective case series.
Participants: Forty-two patients who were diagnosed with STGD in childhood at a single institution between
January 2001 and January 2012.
Methods: A detailed history and a comprehensive ophthalmic examination were undertaken, including color
fundus photography, autoﬂuorescence imaging, spectral-domain optical coherence tomography (SD-OCT), and
pattern and full-ﬁeld electroretinograms. The entire coding region and splice sites of ABCA4 were screened using
a next-generation, sequencing-based strategy. The molecular genetic ﬁndings of childhood-onset STGD patients
were compared with those of adult-onset patients.
Main Outcome Measures: Clinical, imaging, electrophysiologic, and molecular genetic ﬁndings.
Results: The median ages of onset and the median age at baseline examination were 8.5 (range, 3e16) and
12.0 years (range, 7-16), respectively. The median baseline logarithm of the minimum angle of resolution visual
acuity was 0.74. At baseline, 26 of 39 patients (67%) with available photographs had macular atrophy with
macular/peripheral ﬂecks; 11 (28%) had macular atrophy without ﬂecks; 1 (2.5%) had numerous ﬂecks without
macular atrophy; and 1 (2.5%) had a normal fundus appearance. Flecks were not identiﬁed at baseline in 12
patients (31%). SD-OCT detected foveal outer retinal disruption in all 21 patients with available images. Elec-
trophysiologic assessment demonstrated retinal dysfunction conﬁned to the macula in 9 patients (36%), macular
and generalized cone dysfunction in 1 subject (4%), and macular and generalized cone and rod dysfunction in 15
individuals (60%). At least 1 disease-causing ABCA4 variant was identiﬁed in 38 patients (90%), including 13
novel variants; 2 variants were identiﬁed in 34 patients (81%). Patients with childhood-onset STGD more
frequently harbored 2 deleterious variants (18% vs 5%) compared with patients with adult-onset STGD.
Conclusions: Childhood-onset STGD is associated with severe visual loss, early morphologic changes, and
often generalized retinal dysfunction, despite often having less severe fundus abnormalities on examination. One
third of children do not have ﬂecks at presentation. The relatively high proportion of deleterious ABCA4 variants
supports the hypothesis that earlier onset disease is often owing to more severe variants in ABCA4 than those
found in adult-onset disease. Ophthalmology 2015;122:326-334 ª 2015 by the American Academy of Ophthal-
mology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Supplemental material is available at www.aaojournal.org.Stargardt macular dystrophy (STGD) is the most common
form of juvenile-onset macular degeneration; it is inherited
as an autosomal-recessive trait and caused by mutations in
the ABCA4 gene.1e3 Most cases present with central visual
loss in early teenage years and ophthalmoscopy classically
reveals macular atrophy with yellowish-white ﬂecks at the
posterior pole at the level of the retinal pigment epithelium
(RPE).1
A large number of studies have described wide pheno-
typic variability and variable severity in ABCA4-associated
retinopathy. The various phenotypes encompass macular
atrophy without ﬂecks, bull’s-eye maculopathy, fundus ﬂa-
vimaculatus (retinal ﬂecks without macular atrophy), a326  2015 by the American Academy of Ophthalmology. This is an open access
under the CC BY license (http://creativecommons.org/licenses/by/3.0/). Publis
Elsevier Inc.foveal sparing phenotype, cone-rod dystrophy, and “retinitis
pigmentosa.”1e20 There is also considerable allelic hetero-
geneity, with >700 variants in ABCA4 having been reported
to date.1,2,4e34
Patients with childhood-onset STGD tend to develop
early severe visual acuity (VA) loss, markedly compromised
retinal function on electroretinography with generalized rod
and cone system dysfunction, and rapid enlargement of RPE
atrophy and progressive loss of retinal function.5,10,13,35,36
Patients with adult-onset disease are more likely to retain
useful VA for longer and show milder retinal dysfunction at
diagnosis.7,11,13,15,35 There have been no previous studies
speciﬁcally describing the clinical ﬁndings in a large cohortarticle
hed by
http://dx.doi.org/10.1016/j.ophtha.2014.08.012
ISSN 0161-6420/14
Fujinami et al  Childhood-onset Stargardt Diseaseof molecularly conﬁrmed STGD patients presenting and
examined in childhood; the majority of previous reports
relate to clinical features of patients examined in adulthood,
some of whom may have had childhood-onset disease.
The purpose of this study was to describe the detailed
clinical and molecular genetic ﬁndings of a large cohort of
patients from a single center with childhood-onset STGD
examined before 17 years of age.
Methods
Patients
Forty-two patients diagnosed with STGD at <17 years of age,
between January 2001 and January 2012, were ascertained from
the pediatric inherited retinal disease clinics at Moorﬁelds Eye
Hospital. Two subjects have been described in a previous case
report.9 Blood samples were collected and genomic DNA extracted
from peripheral blood leukocytes after obtaining informed consent.
The protocol of the study adhered to the provisions of the Decla-
ration of Helsinki and was approved by the local Ethics Committee
of Moorﬁelds Eye Hospital.
Clinical Evaluation and Electrophysiology
A detailed medical history was obtained and a full ophthalmologic
examination performed. The age of onset was deﬁned as either the
age at which visual loss was ﬁrst noted by the patient or, in the
“asymptomatic” patients, when an abnormal retinal appearance
was ﬁrst detected. The duration of disease was calculated as the
difference between age at onset and age at most recent examination
in childhood. The follow-up data were obtained before the age of
17 years.
Clinical evaluation included best-corrected VA, dilated ophthal-
moscopy, color fundus photography, fundus autoﬂuorescenceTable 1. Classiﬁcation of Phenotype and Genotype in Stargardt Di
Electrophysiologic Assessmen
Fundus Appearance AF Pattern
Grade 1 Normal fundus Type 1 Localized low AF signal
at the fovea surrounded
by a homogeneous
background with/without
perifoveal foci of high or
low signal
Grade 2 Macular and/or
peripheral ﬂecks
without central
atrophy
Grade 3a Central atrophy
without ﬂecks
Type 2 Localized low AF signal
at the macula surrounded
by a heterogeneous
background and widespread
foci of high or low AF
signal extending anterior
to the vascular arcades
Grade 3b Central atrophy
with macular
and/or peripheral
ﬂecks
Grade 3c Paracentral atrophy
with macular
and/or peripheral
ﬂecks, without
central atrophy
Grade 4 Multiple extensive
atrophic changes
of the RPE,
extending beyond
the vascular arcades
Type 3 Multiple areas of low AF
signal at posterior pole
with a heterogeneous
background and/or foci
of high or low signal
AF ¼ autoﬂuorescence; ERG ¼ electroretinography; PERG ¼ pattern electrore
Aligned grades/types/groups of 4 classiﬁcations do not correlate with each otheimaging (AF), spectral-domain optical coherence tomography
(SD-OCT), and electrophysiologic assessment. Best-corrected
Snellen VA was converted to equivalent logarithm of the minimum
angle of resolution (logMAR) VA. Follow-up data of logMAR VA,
color fundus photography, and AF imaging were compared with
those at baseline.
Color fundus photography was performed with a TRC-50IA
Retinal Fundus Camera (Topcon, Tokyo, Japan). Patients were
divided into 1 of 6 fundus appearance groups based on the presence
and location of central (macular) RPE atrophy and yellowish-white
ﬂecks (Table 1).
Autoﬂuorescence images before 2009 were obtained with an
HRA 2 (Heidelberg Engineering, Heidelberg, Germany; excitation
light, 488 nm, barrier ﬁlter, 500 nm; ﬁeld of view, 3030);
imaging after 2009 was undertaken using the Spectralis with
viewing module version 5.1.2.0 (Heidelberg Engineering; excita-
tion light, 488 nm; barrier ﬁlter, 500 nm; ﬁelds of view, 3030
and 5555).37 Patients were classiﬁed into 1 of 3 AF patterns, as
previously described (Table 1).6,36
Spectral domain OCT was undertaken with the Spectralis with
viewing module version 5.1.2.0. The HEYEX software interface
(version 1.6.2.0; Heidelberg Engineering) was used for retinal
thickness measurements.6,37 Central foveal thickness was deﬁned
as the distance between the inner retinal surface and the inner
border of the RPE.6
Electrophysiologic assessment included full-ﬁeld electroreti-
nogram (ERG), and pattern ERG, recorded with gold foil elec-
trodes. Protocols incorporated the recommendations of the
International Society for Clinical Electrophysiology of Vision.38,39
Full-ﬁeld ERGs were used to assess generalized rod and cone
system function and included (i) dark-adapted dim ﬂash 0.01
cd$s$m2 (DA 0.01), (ii) dark-adapted bright ﬂash 11.0 cd$s$m2
(DA 11.0), (iii) light-adapted 3.0 cd$s$m2 30 Hz ﬂicker ERG (LA
3.0 30 Hz), and (iv) light-adapted 3.0 cd$s$m2 at 2 Hz (LA 3.0).
The pattern ERG P50 component was used to assess macular
function. All the components of the ERG and the pattern ERG P50sease, Based on Fundus Appearance, Autoﬂuorescence Pattern,
t, and ABCA4 Variants
ERG Group Genotype Group Classiﬁcation
Group 1 PERG abnormality
with normal
full-ﬁeld ERGs
Genotype A Two or more (likely)
deleterious variants
Group 2 PERG abnormality
with additional
generalized cone
ERG abnormality
Genotype B One deleterious variant
and 1 missense or in-
frame insertion/deletion
variant(s)
Group 3 PERG abnormality
with additional
generalized cone
and rod ERG
abnormality
Genotype C Two or more missense
or in-frame insertion/
deletion variants
tinography; RPE ¼ retinal pigment epithelium.
r.
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previously described electrophysiologic groups (Table 1).5,35Mutation Screening
Blood samples were collected in EDTA tubes and DNA was
extracted with a Nucleon Genomic DNA extraction kit (BACC2;
Tepnel Life Sciences, West Lothian, UK).8 All 50 exons and
exoneintron boundaries of the ABCA4 gene were ampliﬁed using
Illumina Truseq Custom Amplicon protocol (Illumina, San Diego,
CA), followed by sequencing on Illumina MiSeq platform.8,22 The
next-generation sequencing reads were analyzed and compared
with the reference genome GRCh37/hg19, using the variant dis-
covery software NextGENe (SoftGenetics LLC, State College,
PA). All detected possibly disease-associated variants were
conﬁrmed by Sanger sequencing.8,22
All the missense variants identiﬁed were analyzed using 2
software prediction programs: SIFT (Sorting Intolerant from
Tolerant; available from www.sift.jcvi.org/; accessed November 1,
2013), and PolyPhen2 (available from www.gene-
tics.bwh.harvard.edu/pph/index.html; accessed November 1,
2013). Predicted effects on splicing of all the missense and intronic
variants were assessed with the Human Splicing ﬁnder program
version 2.4.1 (available from www.umd.be/HSF/; accessed
November 1, 2013). The allele frequency of all variants was esti-
mated by reference to the Exome Variant Server (NHLBI Exome
Sequencing Project, Seattle, WA; available from www.snp.gs.wa-
shington.edu/EVS/; accessed November 1, 2013).
Patients harboring 2 mutations were classiﬁed into 3 genotype
groups based on mutation type: Group A included patients with 2
deﬁnitely or likely deleterious (severe) variants; group B included
patients with 1 deleterious variant and 1 missense or in-frame
insertion/deletion variants; and group C included individuals with
2 missense or in-frame insertion/deletion variants10 (Table 1).
One disease-associated intronic change of unknown effect was
treated as a deleterious allele owing to the associated severe clinical
phenotype previously reported.5,22 It should be noted, however,
that assigning severity (e.g., a deleterious effect) to a mutation was
not always straightforward, especially for missense alleles and
some variants in splice sites.
Comparison Between Childhood-Onset and Adult-
Onset STGD
To investigate differences between the patients with childhood-
onset STGD and those with adult-onset STGD, clinical and
molecular genetic data of patients with adult-onset STGD ascer-
tained at Moorﬁelds Eye Hospital were reviewed. The compari-
son group consisted of all patients who had adult-onset STGD
(older than 17 years), and who had 2 disease-causing ABCA4
variants.
Statistical analysis was performed using commercially available
software: Excel Tokei 2010 (Social Survey Research Information
Co., Ltd., Tokyo, Japan). The eye used for analysis was selected
according to the Random Integer Generator (available from
www.random.org/). The ManneWhitney U test was applied to
investigate the differences between the 2 groups (childhood-onset
STGD vs adult-onset STGD) in terms of logMAR VA, and central
foveal thickness. The chi square statistic was applied to investigate
the association between selected categorical variables of child-
hood-onset and adult-onset disease, including fundus appearance,
ﬂecks (macular, peripheral, and no ﬂecks), presence of pigmenta-
tion, AF pattern, electrophysiologic group, and genotype group.
P < 0.05 was considered to indicate statistical signiﬁcance.328Results
Forty-two unrelated patients with childhood-onset STGD were
ascertained; the clinical ﬁndings are summarized in Table 2
(available at www.aaojournal.org). There were 22 female and 20
male patients. Eight (19%) were from consanguineous families.
The median age of onset was 8.5 years (range, 3-16), and the
median age at baseline examination was 12.0 years (range, 7e16).
The median logMAR VA at baseline in all 42 patients was 0.74 in
the right eye and 0.74 in the left eye (range, 0.10e1.30 and
0.12e1.40, respectively). The mean duration of disease at baseline
was 2.0 years (range, 0e9). Follow-up data were available for
logMAR VA, fundus photography, and AF imaging, in 24, 14, and
11 patients, respectively. The detailed changes in these parameters
during follow-up are presented in Table 3 (available at
www.aaojournal.org).
The median logMAR VA at baseline in the 24 patients that
were monitored was 0.75 in the right eye and 0.75 in the left eye
(range, 0.10e1.30 and 0.12e1.30, respectively); the median log-
MAR VA at follow-up was 1.00 in the right and 1.00 in the left eye
(range, 0.05e1.40 and 0.20e1.60, respectively) at a median age of
15.0 years (range, 12e16). Fifteen patients (15/42; 36%) had
logMAR or 1.0 VA in the better eye at baseline. Thirteen of 24
patients (54%) with available follow-up data had logMAR VA of
1.0 in the better eye at follow-up (range, 11e16). Follow-up data
were available in 14 of 27 patients with VA better than logMAR
1.0 in the better eye at baseline; 6 (43%) had logMAR of 1.0 VA
in the better eye at follow-up (range, 13e15).
Color fundus photographs, AF images, and SD-OCT images of
5 representative cases are shown in Figure 1. Baseline color fundus
photographs were obtained in 39 patients (Table 2). Among the 39
patients, there was 1 (2.5%) with a grade 1 fundus appearance at
baseline, 1 (2.5%) with grade 2, 11 (28%) with grade 3a, and 26
(67%) with grade 3b. There were no patients with a grade 3c or
grade 4 fundus appearance. Central atrophy was present in 37 of
the 39 patients (95%) at baseline; ﬂecks were detected at the
macula in 4 of the 39 patients (10%) and in the periphery in 23
(59%), with no visible ﬂecks in 12 individuals (31%; Table 2).
Retinal pigmentation was present in 2 of the 39 patients (5%;
patients 24 and 34).
Serial color fundus photographs were available in 14 patients
(Table 3), 3 of whom showed a fundus grade transition. Macular
ﬂecks, which were not present at baseline, developed in 2 subjects
(patients 7 and 13) and macular and peripheral ﬂecks became
visible in 1 individual (patient 26). Color fundus photographs and
AF images of 4 representative cases who developed ﬂecks during
the follow-up interval are shown in Figure 2.
Patients 17 and 18 had ﬁne dots at the central macula sur-
rounded by numerous peripheral ﬂecks, classiﬁed into fundus
grade 3b (patient 17; Fig 3). Clinical and molecular genetic data of
these 2 patients have been previously described.9 Only 1 patient
had asymmetric fundus ﬁndings, with a central atrophic-appearing
lesion with peripheral ﬂecks extending anterior to the vascular
arcades in the right eye, and macular atrophy with ﬂecks, subretinal
ﬁbrosis, and hyperpigmentation at the level of RPE in the left eye
(patient 29; Fig 3).
We obtained AF images for 32 patients at baseline (Table 2).
There were 10 of the 32 patients (31%) with type 1 AF pattern, 22
(69%) with type 2 AF, and no subjects with type 3 AF. Serial AF
images were obtained in 11 patients during the follow-up interval
(Table 3); no patient demonstrated an AF grouping transition.
We obtained SD-OCT images for 21 patients at baseline
(Table 2). Outer retinal disruption at the fovea was present in all 21
patients. The median central foveal thickness of the right and left
eyes was 60.0 and 55.0 mm, respectively (range, 33e138 and
Figure 1. Color fundus photographs, autoﬂuorescence, and spectral-domain optical coherence tomographic images of 5 representative cases with childhood-
onset Stargardt Disease (patients 2, 21, 15, 37, and 9). Color fundus photographs of patient 2 shows normal ﬁndings at age 7 (fundus grade: 1). Patient 21 has
numerous ﬂecks at the posterior pole without central atrophy (fundus grade: 2) and autoﬂuorescence (AF) imaging demonstrates widespread multiple foci of
high and low AF signal at the posterior pole with a heterogeneous background (AF type 2). Spectral-domain optical coherence tomography (SD-OCT)
identiﬁes marked outer retinal loss at the central macula. Patient 15 has central atrophy without ﬂecks (fundus grade: 3a) and AF imaging demonstrates a
localized low AF signal at the fovea with a high signal edge surrounded by a homogeneous background (AF type: 1). SD-OCT detects marked outer retinal
loss at the central macula. Patient 37 has central atrophy with macular ﬂecks (fundus grade: 3b) and a localized low AF signal at the fovea surrounded by a
homogeneous background with perifoveal foci of high signal (AF type: 1). SD-OCT shows outer retinal loss at the central macula. Patient 9 has central
atrophy with peripheral ﬂecks extending anterior to the vascular arcades (fundus grade: 3b) and a localized low AF signal at the macula surrounded by a
heterogeneous background and widespread foci of high AF signal extending anterior to the vascular arcades (AF type: 2). SD-OCT reveals outer retinal
disruption at the macula. Pt ¼ patient.
Fujinami et al  Childhood-onset Stargardt Disease35e140, respectively). Eighteen of the 21 patients (86%) had
severe foveal thinning in both eyes (<100 mm).
Electrophysiologic assessment was performed in 25 patients at
baseline (Table 2). Nine of the 25 patients (36%) were in ERG group
1 (isolatedmacular dysfunction), 1 (4%)was in ERG group 2, and 15
(60%) were in ERG group 3 (generalized cone and rod dysfunction).Molecular Genetics
Detailed molecular genetic results including in silico analysis to
assist in the prediction of pathogenicity of the variants are shown in
Table 4 (available at www.aaojournal.org). Forty-six ABCA4 vari-
ants were identiﬁed: 27 missense, 7 splice-site alterations,329
Figure 2. Color fundus photographs and autoﬂuorescence (AF) images of 4 representative cases developing macular ﬂecks during follow-up (patients 7, 13,
26, and 12). Color photograph of patient 7 at baseline shows subtle central atrophy without ﬂecks (fundus grade 3a). At baseline, AF imaging demonstrates a
localized low AF signal surrounded by an irregular high signal (AF type 1). Five years later, there is marked central atrophy with visible macular ﬂecks
(fundus grade 3b) and AF imaging demonstrates a localized low AF signal at the fovea with perifoveal foci of high signal (AF type 1). Patient 13 shows
central atrophy with no visible ﬂecks at baseline (fundus grade 3a), with AF imaging showing a localized low AF signal surrounded by subtle foci of high AF
signal at the macula (AF type 1). Six years later, there are marked and increased macular ﬂecks, also clearly seen on AF imaging (fundus grade 3b; AF type
1). Patient 26 has central atrophy with no visible ﬂecks at baseline (fundus grade 3a), but marked ﬂecks corresponding to foci of high signal on AF imaging
are present 4 years later (fundus grade 3b; AF type 2). Patient 12 shows central atrophy with early subtle peripheral ﬂecks at baseline (fundus grade 3b) and
AF imaging demonstrates a localized low AF signal with subtle foci of high AF signal extending anterior to the vascular arcades (AF type 2). Two years later,
there are marked and increased macular and peripheral ﬂecks, which are also well-deﬁned on AF imaging (fundus grade 3b; AF type 2). Pt ¼ patient.
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disease-associated intronic variant for which the exact pathogenic
mechanism is not known. Thirteen novel deﬁnitely or highly likely
disease-causing variants were identiﬁed: p.Gln8fs, p.Cys519*,
p.Asp586Gly, p.Arg587Lys, p.Glu905fs, p.Tyr1027*, p.Met1066-
Arg, p.Arg1097*, p.Thr1721fs, p.Tyr1770Asp, p.Ala1739dup,
p.Ser2072Asn, and c.6817-2A>C (Table 4). Four homozygous
variants (p.Glu905fs, p.Glu1022Lys, p.Tyr1027*, and
c.6479þ1G>A) were identiﬁed in patients from consanguineous
families and the other 42 variants were detected in heterozygous
state. Four of 8 patients from consanguineous families had homo-
zygous variants (patients 3, 5, 6, and 28), 2 had compound hetero-
zygous variants (patients 2 and 17), and 2 had no variants identiﬁed
(patients 1 and 4).330At least 1 disease-causing ABCA4 variant was detected in 38 of
the 42 patients (90%); of these, 2 variants were identiﬁed in 34
(81%) and 1 variant in 4 (9.5%; Tables 2 and 4). Only 4 of the 42
individuals (9.5%) had no variants identiﬁed. The 34 patients
harboring 2 disease-causing variants were classiﬁed based on the
number and mutation type (with suggested severity) into 3 geno-
type subgroups: 7 patients (21%) in genotype group A, 15 (44%) in
group B, and 12 (35%) in group C (Table 2).
Comparison Between Childhood-Onset and Adult-
Onset STGD
Sixty-four patients with adult-onset STGD harboring 2 disease-
causing ABCA4 variants were reviewed. The clinical and molecular
Figure 3. Color fundus photographs, autoﬂuorescence (AF), and spectral-domain optical coherence tomographic images of 2 molecularly proven cases with
“atypical” clinical features of childhood-onset Stargardt Disease (patients 17 and 29). Color photograph of patient 17 shows ﬁne dots at the central macula
surrounded by numerous peripheral ﬂecks and AF imaging demonstrates well-deﬁned dots associated with a high signal at the central macula surrounded by a
ring of increased AF signal and numerous foci with high and low signal extending to the peripheral retina. Outer retinal loss at the macula is present on SD-
OCT. Patient 29 has asymmetric fundus ﬁndings with central atrophy and peripheral ﬂecks in the right eye and macular atrophy with ﬂecks, subretinal
ﬁbrosis, and hyperpigmentation at the level of the retinal pigment epithelium in the left eye. Pt ¼ patient.
Figure 4. Comparison of the distribution of fundus appearances, presence of pigmentation, electrophysiologic group, and genotype group between a cohort
with childhood-onset Stargardt disease and a group with adult-onset Stargardt disease. There are signiﬁcant differences in terms of fundus appearance clas-
siﬁcation, presence of pigmentation, and genotype group classiﬁcation (*P < 0.05). A higher proportion of patients with childhood-onset Stargardt disease are
in electrophysiologic group 3 compared with adult-onset Stargardt disease, but this difference does not attain signiﬁcance. ERG = electroretinography.
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onset STGD harboring 2 disease-causing ABCA4 variants and the
aforementioned 64 patients with adult-onset STGD (Table 5,
available at www.aaojournal.org; Fig 4).
There were signiﬁcant differences in terms of fundus appear-
ance classiﬁcation (chi-square ¼ 23.2; P ¼ 0.001), presence of
pigmentation (chi-square ¼ 14.9; P ¼ 0.000), genotype group
classiﬁcation (chi-square ¼ 7.3; P ¼ 0.003), and central foveal
thickness in the selected eye (P ¼ 0.012; Table 5, available at
www.aaojournal.org; Figs 4 and 5, available at www.aaojournal.org);
with childhood-onset STGD being associated with less retinal
pigmentation, a greater proportion of patients harboring deleterious
alleles, and a thinner central fovea. No differences were identiﬁed
in terms of location of ﬂecks (chi-square ¼ 4.0; P ¼ 0.136), AF
pattern (chi-square ¼ 5.6; P ¼ 0.061), electrophysiologic group
(chi-square ¼ 3.8; P ¼ 0.148), or logMAR VA in the selected eye
(P ¼ 0.781). However, a greater proportion of patients with
childhood-onset STGD were in ERG group 3 (10/18; 56%)
compared with adult-onset STGD (18/59 [31%]; Table 5; Fig 4),
but the difference, although showing a strong trend, did not attain
signiﬁcance (Fig 4).
Discussion
This manuscript reports a series of childhood-onset patients
with molecularly conﬁrmed STGD, and compares the
genetic, clinical, and electrophysiologic data with those in
an adult-onset group.
The classical phenotype of STGD is characterized by the
presence of yellowish-white fundus ﬂecks and macular
atrophy, but the fundus appearance can be variable.1,3,12,13
Fishman described 4 groups based on fundus appearance
and electrophysiologic ﬁndings3; the author did not distin-
guish between childhood-onset and adult-onset disease. In
addition, the classiﬁcation did not fully encompass the range
of phenotypes present in childhood-onset disease and thus
was modiﬁed for the present study (Table 1). Most children
in this study had the classical fundus appearance of STGD
with macular atrophy and macular and/or peripheral ﬂecks,
but one third of children had no visible ﬂecks at presenta-
tion. Subsequent development of ﬂecks was observed dur-
ing the follow-up interval in 3 of these 12 patients (Fig 2).
Similar development of macular/peripheral ﬂecks over time
have also been described in a young adult patient with
STGD.18
There were no children with paracentral atrophy without
central atrophy (observed in the foveal sparing phenotype, a
milder phenotype seen in a minority of patients with
STGD).7,11,13,15 This observation is in keeping with previ-
ous reports that patients with a foveal sparing phenotype
typically present in later adult life.7,15 The subset with a
foveal-sparing phenotype show relatively preserved foveal
structure, which results in a relatively wide CFT range in the
adult-onset STGD group (Fig 5).
Marked disruption of foveal outer retinal structure was
present on SD-OCT in all children imaged, indicating that
changes in foveal structure occur early in the disease pro-
cess. Visual loss may precede ophthalmoscopic abnormal-
ities in childhood-onset STGD and this may lead to
nonorganic visual loss being considered. In such cases,332SD-OCT imaging and/or electrophysiologic assessment will
avoid misdiagnosis.18 The early foveal involvement in
STGD without ﬂecks, or other AF imaging evidence of
increased levels of lipofuscin in the RPE, lend support to the
hypothesis that A2E, which is elevated in STGD, may be
directly toxic to cone photoreceptors.40,41
Of the 24 patients, 9 (36%) were in ERG group 1, 1
(4%) in ERG group 2, and 15 (60%) in ERG group 3. A
greater proportion of patients were in group 3 compared
with the cohort with adult-onset disease, indicating that
childhood-onset STGD is more likely to be associated with
generalized retinal dysfunction. This is further evidence for
childhood-onset STGD having a more severe retinal
phenotype.5,6,35
Twenty-two patients (58%) had 1 deleterious variant
and 7 subjects (18%) had 2 deleterious variants, which
was signiﬁcantly higher than observed in the adult-onset
cohort (45% and 5%, respectively). The 5 patients (71%)
with available ERGs in genotype group A (harboring 2
deleterious variants) all had generalized rod and cone
system dysfunction (ERG group 3). These ﬁndings when
taken together suggest that patients harboring deleterious
ABCA4 variants are more likely to have an earlier pre-
sentation (childhood) and a more severe functional
phenotype.5
There are potential limitations of this study, including the
deﬁnition of age of onset and choosing to classify child-
hood-onset as before the age of 17. The age of onset was
deﬁned as either the age at ﬁrst symptom or the age when a
retinal abnormality was ﬁrst detected in “asymptomatic”
patients. These 2 groups (symptomatic and asymptomatic)
may have different clinical characteristics, including the
symptomatic patients would be expected to have foveal
involvement and thereby reduced VA. However, the vast
majority of children were symptomatic in our cohort. It is
also possible that dividing patients by age 17 may poten-
tially introduce a selection bias.
This study speciﬁcally addresses, for the ﬁrst time, the
clinical features and molecular genetic ﬁndings of child-
hood-onset STGD in a substantial group of patients.
Childhood-onset disease is associated with more severe
VA loss from the early stages of disease. The classical
ﬂecks are not always present at diagnosis, but can appear
later in the course of disease. Generalized cone and rod
system dysfunction is more common than in adult-onset
disease, in keeping with a more severe phenotype. Two or
more disease-causing variants were detected in >80% of
children and a higher proportion of deﬁnitely or possibly
deleterious variants were demonstrated compared with
adult-onset STGD, which is likely to underlie the earlier
onset and more severe phenotype in childhood. The rapid
deterioration of function in childhood-onset disease sug-
gests that the investigation of novel therapies in this age
group is more likely to lead to timely recognition of any
treatment effect compared with adults with more slowly
progressive disease.
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